Sochal M, Małecka-Panas E, Gabryelska A, et al. - Researchers did the study to examine the serum level of brain-derived neurotrophic factor (BDNF) in Crohn disease (CD) patients and to analyze the effect of anti-TNF therapy on the BDNF level and its impact on sleep, mood, and pain parameters. The sample consisted of 58 CD patients and 26 healthy controls (HC). The severity of insomnia symptoms was evaluated by the Athens Insomnia Scale (AIS). Increased BDNF levels in CD patients suggest that it may be involved in the disease's pathogenesis and clinical course. There was no correlation found between clinical severity and BDNF. There were positive relationships between the BDNF level and the results of AIS, the severity of pain measured using the Visual Analogue Scale and the Laitinen Pain Scale, but not Beck Depression Inventory. There were no differences in BDNF levels before and after 14 weeks of anti-TNF-α therapy. More research into BDNF could lead to a better understanding of the effects of sleep and pain on the course of CD.